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1158 Abstracts October 2013displacement of the tibial nerve and compression of popliteal vein due to PAA
mass effect. The aneurysm sac was then closed over itself, fully decompressing
the popliteal vein.
Conclusions: OBGL is the gold standard for PAA repair. However,
late term complications can arise, and therefore surveillance with physical
exam and Doppler should be continued in these patients.
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Objectives: This study analyzes weather endoleaks behave differently
following endovascular abdominal aortic aneurysm repair (EVAR) for
rupture vs elective abdominal aortic aneurysm (AAA) repair.
Methods: From 2002 to 2012, 1728 patients underwent EVAR for
treatment of rupture (n ¼ 152, 8.8%) and elective (n ¼ 1576, 91.2%)
infrarenal AAA. Follow-up included computed tomographic angiogram at
1, 6, and q 12 months. All type I endoleaks were treated at the time of diag-
nosis, and persistent type II endoleaks at >6 months following EVAR
without a decrease in AAA sac underwent translumbar and transfemoral
embolization procedures. Data was prospectively collected in a vascular
database.
Results: Over a mean follow-up of 38.5 months, patients following
ruptured-EVAR (r-EVAR) had a signiﬁcantly lower incidence of type II
endoleaks when compared with elective (e-EVAR) (Table). Although the
incidence of type I endoleaks is similar following r-EVAR and e-EVAR
(Table), the r-EVAR patients with endoleaks required stent graft explant
more frequently (7/26, 26.9% vs 32/475, 6.7%; P < .01), and e-EVAR
patients undergo percutaneous embolization procedures more frequently
(298/475, 62.7% vs 11/26, 42.3%, P < .05). The need for stent graft
extensions in patients with endoleaks is comparable in both r-EVAR and
e-EVAR (8/26, 30.8% vs 145/475, 30.5%) groups.
Conclusions: When compared with e-EVAR, r-EVAR patients expe-
rience a similar incidence of type I endoleaks, and a signiﬁcantly lower inci-
dence of type II endoleaks. However, r-EVAR patients with any endoleaks
are at a signiﬁcantly higher risk for stent graft explant, while endoleaks in e-
EVAR patients can be more frequently managed by percutaneous endovas-
cular means.
Table.
rEVAR (n ¼ 152) eEVAR (n ¼ 1576) P valueAll endoleaks 26 (17.1%) 475 (30.1%) <.01
Type 1 endoleaks 12 (7.9%) 136 (8.6%) NS
Type 2 endoleaks 14 (9.2%) 339 (21.5%) <.01Does Complete Eradication of Isolated Type II Endoleaks with Glue
Embolization Affect EVAR Outcomes?
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Objectives: Indications for treatment, techniques, and reported
outcomes following type II endoleak embolization remain inconsistent.
We investigated endovascular abdominal aortic aneurysm repair (EVAR)
outcomes with an exclusive focus on patients with isolated type II endoleaks
(IT2) that were completely eradicated via N-butyl cyanoacrylate (N-BCA)
embolization alone.
Methods: We retrospectively reviewed a series of 24 patients with
completely eradicated IT2 for secondary interventions, aneurysm growth/
regression, aneurysm rupture, and aneurysm-related and overall mortality.
Indications for treatment were persistent ($6 months) IT2 and growing
($5 mm; n ¼ 11) or stable (n ¼ 13) aneurysm sacs. N-BCA was injected
into the endoleak nidus transarterially (n ¼ 17), via direct sac puncture
(n ¼ 6), or both (n ¼ 1). Patients were followed by computed tomography
angiography and/or duplex ultrasound.
Results: Complete eradication was achieved in all patients with no
recurrent IT2 at last follow-up. Mean time between EVAR and emboliza-
tion was 29 6 22.8 months and follow-up was 41 6 22.3 months. Overall
mortality was 8 (33%) including one death following an explant for aneu-
rysm rupture (due to a type Ia endoleak) and two deaths from unknown
causes. Aneurysm outcomes following embolization are summarized in
the Table.
Conclusions: There is a disconnect between overall sac behavior
and presence or absence of IT2. Thus, we cannot demonstrate that
complete eradication of persistent IT2 has any effect on EVAR
outcomes.
